Abstract
In Canada, intravenous immune globulin (IVIG) use has increased by 115% over the past 7 to 8 years. Given this increased usage, Canadian Blood Services and the National Advisory Committee on Blood and Blood Products for Canada identified the need to develop and disseminate evidence-based guidelines to facilitate appropriate IVIG use. As a result, guidelines for IVIG use in hematologic and neurologic conditions have been developed and are published in this supplement of Transfusion Medicine Reviews. This commentary provides a brief description of the process used to develop these guidelines and includes a summary of the recommendations for IVIG use in the various conditions evaluated.
| Original language | English |
|---|---|
| Pages (from-to) | S3-S8 |
| Journal | Transfusion Medicine Reviews |
| Volume | 21 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - Apr 2007 |
ASJC Scopus Subject Areas
- Hematology
- Clinical Biochemistry
- Biochemistry, medical
PubMed: MeSH publication types
- Journal Article
- Practice Guideline
Fingerprint
Dive into the research topics of 'Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions'. Together they form a unique fingerprint.Cite this
Robinson, P., Anderson, D., Brouwers, M., Feasby, T. E., & Hume, H. (2007). Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions. Transfusion Medicine Reviews, 21(SUPPL. 1), S3-S8. https://doi.org/10.1016/j.tmrv.2007.01.004